These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16205839)

  • 21. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
    Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
    Cao Z; Harris N; Kozielski A; Vardeman D; Stehlin JS; Giovanella B
    J Med Chem; 1998 Jan; 41(1):31-7. PubMed ID: 9438019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationship of alkyl 9-nitrocamptothecin esters.
    Cao ZS; Pantazis P; Mendoza J; Early J; Kozielski A; Harris N; Giovanella B
    Acta Pharmacol Sin; 2003 Feb; 24(2):109-19. PubMed ID: 12546717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
    Gliniak B; Le T
    Cancer Res; 1999 Dec; 59(24):6153-8. PubMed ID: 10626806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations.
    Pigatto MC; Roman RM; Carrara L; Buffon A; Magni P; Dalla Costa T
    Eur J Pharm Sci; 2017 Jan; 97():70-78. PubMed ID: 27816627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers.
    Li G; Yu K; Li F; Xu K; Li J; He S; Cao S; Tan G
    J Ethnopharmacol; 2014 Apr; 153(2):521-30. PubMed ID: 24631140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
    Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
    Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
    Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translational pharmacokinetic/pharmacodynamic analysis in cancer pharmacology: a tool to maximize the value of antitumor efficacy from tumor bearing mice.
    Wong H; Gould SE
    Drug Discov Today Technol; 2016; 21-22():51-56. PubMed ID: 27978988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
    Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 9-Nitrocamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies.
    Han Z; Wyche JH; Sands H; Pantazis P
    Anticancer Res; 2001; 21(3B):1823-7. PubMed ID: 11497265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect.
    Silver DF; Piver MS
    Gynecol Oncol; 1999 May; 73(2):280-4. PubMed ID: 10329047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.
    Pantazis P; Early JA; Mendoza JT; DeJesus AR; Giovanella BC
    Cancer Res; 1994 Feb; 54(3):771-6. PubMed ID: 8306340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK; Chen CL; Dong Y; Uckun FM
    Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro and in vivo stability of 9-nitrocamptothecin lactone form in rats].
    Chen J; Ping QN; Guo JX; Liu L; Chu XZ; Song MM
    Yao Xue Xue Bao; 2005 Oct; 40(10):888-92. PubMed ID: 16408803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
    Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
    Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.